Soft Tissue Sarcoma

• (101-21) A Phase 1 Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 with a Cohort Expansion at the RP2D in Patients with Advanced Solid Tumors
• (131-17) A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 (IT-01) (Phase 1 clinical trial, appropriate for patients with all solid tumors.)

• (157-17) FID-007 in Treating Participants With Advanced Solid Tumors (Phase 1 clinical trial, appropriate for patients with advanced solid malignancies.)

• (178-18) A Phase 1-2 Study of the Safety, Pharmacokinetics, and Activity of ASTX029 in Subjects With Advanced Solid Tumors
• (187-19) A Phase 1/2 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody as Monotherapy and in Combination With AGEN2034, an Anti-PD-1 Monoclonal Antibody, in Subjects with Advanced Cancer (Phase 1 clinical trial, appropriate for patients with advanced solid tumors.)
• (188-18) A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors (Phase 1 clinical trial, appropriate for patients with advanced solid tumors.)